日本庆应义塾大学宣布，他们已经成功将iPS干细胞移植到一名脊髓损伤患者体内，这是同类试验中的第一个人体临床试验。

Keio University in Japan announced that it had successfully transplanted iPS stem cells into a spinal cord injury patient, the first human clinical trial of its kind.

庆应义塾大学的外科医生想研究诱导多能干细胞（iPS）是否可以用于治疗这种脊髓损伤。

Surgeons at Keio University wanted to study whether induced pluripotent stem cells (iPS) could be used to treat this spinal cord injury.

iPS细胞的工作原理是刺激成熟的特化细胞“重新编程”培育成干细胞状态，然后诱导它们重新分化为不同类型的细胞。这项技术由Shinya Yamanaka和日本京都大学的其他人开发，并因此获得了2012年诺贝尔生理学或医学奖。

iPS cells work by stimulating mature, specialized cells to return to a stem cell state and then inducing them to redifferentiate into different types of cells. The technique was developed by Shinya Yamanaka and others at Kyoto University in Japan , for which he won the 2012 Nobel Prize in Physiology or Medicine.

该治疗方法就是采集患者的体细胞进行体外培养，并利用iPS技术将这些体细胞诱导成各种所需的细胞，其复制能力可用于修复受损的组织或器官。

The patient’s cells are extracted for in vitro culture, and these cells are induced into various desired cells using iPS technology, and their replication ability can be used to repair damaged tissues or organ.

庆应大学的研究人员尝试利用iPS衍生的神经干细胞治疗严重的脊髓损伤。

Researchers at Keio University used iPS-derived neural stem cells to treat severe spinal cord injuries.

事实上，该临床试验早在2019年就获得了批准，之后又因新冠病大流行而暂停了该试验。

In fact, the clinical trial was approved as early as 2019 before the trial was put on hold due to the Covid-19 pandemic.

据报道，该研究团队在上个月的手术中已将200多万个由iPS衍生的神经干细胞移植到脊髓损伤患者的脊髓中。

It is reported that the research team has transplanted more than 2 million iPS-derived neural stem cells into the spinal cord of patients with spinal cord injury during surgery last month.

目前，这名患者的详细情况仍有待保密，中村的团队表示，这项脊髓损伤干细胞治疗试验将集中在14-28天内的脊髓损伤患者身上。

At present, the details of this patient are still confidential, and Nakamura ‘s team said that this trial of stem cell treatment of spinal cord injury will focus on people with spinal cord injury within 14-28 days.